DNA binding of activator protein-1 is increased in human mesangial cells cultured in high glucose concentrations  by Wilmer, William A. & Cosio, Fernando G.
DNA binding of activator protein-1 is increased in human
mesangial cells cultured in high glucose concentrations
WILLIAM A. WILMER and FERNANDO G. COSIO
Division of Nephrology, Department of Medicine, The Ohio State University, Columbus, Ohio, USA
DNA binding of activator protein-1 is increased in human mesangial
cells cultured in high glucose concentrations. Human mesangial cells
(HMC) grown in high glucose environments synthesize excessive amounts
of extracellular matrix proteins (ECM). The promoter regions of certain
ECM genes contain TPA (phorbol ester)-responsive element (TRE)
motifs that bind the transcription factor, activator protein-1 (AP-1), a
complex of Jun and other phosphoproteins. AP-1 binding to the TRE
promoter is regulated by the quantity, composition and post-translational
modifications of proteins in the AP-1 complex. We report an increased
binding of AP-1 to TRE oligonucleotides in HMC cultured chronically (5
days) in high glucose environments (30 mM d-glucose). This increased
binding is not due to differences in the nuclear quantity of AP-1 proteins
or in the composition of the AP-1 complex when compared to AP-1
proteins from cells grown in normal glucose (5 mM d-glucose). A 30 mM
l-glucose environment also increased AP-1 binding, but to a degree less
than d-glucose. The increased AP-1 binding was partly reversed by
treatment of HMC with Calphostin C or Bisindolylmaleimide I suggesting
a partial role of the protein kinase C (PKC) pathway in mediating AP-1
binding. AP-1 binding was unaffected by treatment of cells with the MEK
inhibitor PD 98059. In addition, increased AP-1 binding persisted for at
least 48 hours after media glucose concentrations were normalized. The
level of Jun-NH2-terminal kinase (JNK) activity and the phosphorylation
of the JNK kinase, SEK1, were unchanged by chronic high glucose
concentrations. These studies suggest that in HMC cultured in chronic
high glucose, post-translational modifications increase the binding of AP-1
to the TRE motif.
Diabetic nephropathy frequently results in progressive renal
deterioration and the need for dialytic intervention or renal
transplantation. Histologically, the progression of diabetic ne-
phropathy correlates closely with expansion of the glomerular
mesangium [1–3]. Mesangial expansion in diabetes is principally
due to the accumulation of matrix proteins [2, 4] rather than a
result of increased mesangial cell proliferation. This matrix accu-
mulation occurs through an overproduction of matrix proteins
[4–8] and impaired degradation of secreted matrix components
[9–11]. Key observations regarding the pathogenesis of these
defects include: (1) high concentrations of glucose in vitro induce
mesangial cells to overproduce extracellular matrix (ECM) pro-
teins [6, 12, 13]; (2) diabetic glomeruli and mesangial cells
exposed in vitro to high levels of glucose overproduce transform-
ing growth factor-b (TGF-b) [14–16], a cytokine that stimulates
matrix production and inhibits matrix degradation.
Mesangial cell expression of TGF-b1 and certain ECM proteins
is dependent on activation of TPA (phorbol ester)-responsive
elements (TREs) within the promoter region of these genes. AP-1
may also bind and activate ECM genes that contain promoter
cyclic-AMP responsive elements (CREs) due to base-pair similar-
ities of the CRE to the TRE [17]. Therefore, an increased binding
of AP-1 to certain gene promoters may be relevant to the
pathogenesis of diabetic nephropathy. Promoter region TREs and
CREs are bound by the transcription factor, activator protein-1
(AP-1), a dimer of Jun and other phosphoproteins. AP-1 binding
to the TRE is stimulated when Jun, which in quiescent cells is
COOH-terminus phosphorylated, becomes dephosphorylated
[18] through the indirect effects of protein kinase activation.
Specifically, protein kinase C (PKC) and the mitogen activated
protein kinase (MAPK), ERK [19, 20] can increase AP-1 binding
by modulating other kinases that keep Jun phosphorylated at the
COOH-terminus. Since several authors have demonstrated in
various cell types that high glucose conditions cause an acute as
well as chronic activation of PKC, AP-1 binding may be increased
in the diabetic state.
Previous studies have shown that acute exposure of mesangial
cells to high glucose concentrations increases mRNA levels and
nuclear protein content of the two AP-1 components, c-Jun and
c-Fos [21]. Conversely, we showed that c-fos mRNA levels are
significantly reduced in human mesangial cells (HMC) exposed
chronically to high glucose concentrations, despite the presence of
agonists that classically stimulate c-fos trancription [22]. Interest-
ingly, these inhibitory effects on c-fos appeared to be mediated by
PKC.
Unfortunately, extrapolating the amount of AP-1 mRNA or
protein within the cell to changes in TRE transcription is prob-
lematic for several reasons. First, the synthesis and nuclear
quantity of AP-1 proteins does not always parallel their mRNA
expression [23]. Increases in jun transcription often exceed Jun
protein synthesis due to translational inefficiency caused by an
extremely long 59 untranslated region of the gene [24]. Second,
AP-1 can either stimulate or suppress gene transcription depend-
ing on its protein composition [25, 26]. AP-1 composed of Jun-Fos
heterodimers bind DNA more avidly than Jun homodimers or
dimers composed of Jun and other leucine-zipper proteins, such
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as ATF/CREB. Third, the phosphorylation status of AP-1 pro-
teins directs not only their DNA binding but also the subsequent
transcription of TRE genes after binding [18, 27, 28]. After DNA
binding, Jun is serine phosphorylated at an NH2-terminus trans-
activation domain [29]. Currently, the only accepted NH2-termi-
nal kinase capable of modifying AP-1 are the Jun-NH2-terminal
kinases (JNK), a subfamily of the MAPK superfamily [29–31].
In this current study, the effects of chronic glucose exposure on
DNA binding of AP-1 were investigated. To provide a more
comprehensive evaluation of glucose effects on TRE-mediated
transcription, the chronic effects of high glucose concentration on
JNK activity were also assessed.
METHODS
Cell culture
Human mesangial cells were harvested from kidneys deemed
unacceptable for transplantation, and were characterized as de-
scribed previously [22]. At least four different donor cell types
were used throughout these studies at passages 5 to 8. Cells were
cultured in six-well plates with Media 199 (Gibco BRL, Grand
Island, NY, USA) containing 10% heat-inactivated fetal calf
serum, 100,000 U/liter penicillin G sodium, 100 mg/liter strepto-
mycin sulfate (Gibco BRL). Unless specified otherwise in the text,
they were conditioned for varying periods up to five days in either
5 mM d-glucose (normal glucose, NG) or 30 mM d-glucose (high
glucose, HG) concentrations in the presence of serum-containing
media without supplemental insulin.
Nuclear protein harvest and electrophoretic mobility shift assays
Nuclear proteins were harvested from HMC chilled for five
minutes, washed twice in cold PBS and centrifuged at 4°C. The
nuclear protein extracts were obtained using the protocol of
Dignam, Lebovitz and Roeder [32] as modified by Osborn,
Kunkel and Nabel [33] with the addition to each buffer of 5 mg/ml
of the protease inhibitor leupeptin (Sigma Chemicals, St. Louis,
MO, USA). Protein concentrations were measured by bicinchi-
noic acid technique (Pierce Analytical Research, Rockford, IL,
USA) using bovine serum albumin as standards. Electrophoretic
mobility shift assays (EMSA) were performed by adding 10 mg
nuclear protein to an incubation buffer containing 10 mM Tris, 100
mM NaCl, 5 mM EDTA, 4% glycerol and 2 mg poly dI-dC
(Pharmacia, Upsala, Sweden). A double-stranded oligonucleotide
containing two consensus TPA responsive elements (TREs;
Gibco, BRL) was end-labeled with g-32P-ATP (NEN-Du Pont,
Boston, MA, USA) by T4 polynucleotide kinase. Unlabeled
32P-ATP was separated from the oligonucleotide mixture with
D-25 Sephadex columns. Unless specified otherwise, 0.2 ng of the
labeled TRE probe was added to the incubation buffer for 20
minutes at room temperature and the protein-DNA complexes
were resolved at 4°C on 5% non-denaturing polyacrylamide gels
in 0.253 TBE buffer. Thereafter, the gels were dried and exposed
to autoradiography film at 270°C. DNA-protein complexes were
demonstrated as bands retarded in their migration through the
gel. Specificity of the bands as AP-1/TRE complexes was con-
firmed by incubating the nuclear protein with labeled TRE probe
and either 503 unlabeled probe or 503 unlabeled non-specific
oligonucelotide probe.
Supershift assays were performed by adding 0.5 mg polyclonal
antibody recognizing Fos proteins (anti-pan-Fos antibody), Jun
proteins (anti- cJun, Jun B, or Jun D antibody) or CREB proteins
(anti-ATF/CREB antibody; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) for 30 minutes at 4°C prior to the addition of the
TRE probe. EMSA were thereafter performed as described.
Protein kinase C (PKC) and ERK inhibition experiments were
performed as follows. Human mesangial cells grown for five days
in normal glucose (NG) or high glucose (HG) media were treated
with the PKC inhibitors Calphostin C (5 to 100 nM) or Bisindolyl-
maleimide I (50 to 100 nM; Calbiochem-Novabiochem, La Jolla,
CA, USA) for one hour. Calphostin C was activated by exposure
to ambient fluorescent light during incubation with the HMC [34].
Some cells were treated with the MEK inhibitor PD 098059 (New
England Biolabs,Inc., Beverly, MA, USA) for 60 minutes at a
concentration (25 mM) that inhibits ERK pathway activity in HMC
[35]. The cells were thereafter lysed, nuclear proteins harvested
and EMSA performed as described.
Relative differences in the quantity of the retarded complexes
observed in EMSA were grossly assessed by differences in band
intensity, but in some experiments quantitated by excision of the
band and scintillation counting.
Equilibrium dissociation constants
The dissociation of AP-1 bound to DNA (Kd) relates to the
affinity of the complex (K) as: Kd 5 1/K [36]. Kd and the maximal
binding threshold (Bmax) of the complex can be estimated via
EMSA [37]. In these experiments, EMSA were performed using
10 mg nuclear protein to which was added increasing quantities of
labeled TRE oligonucleotide probe. After EMSA, the amount of
bound and unbound DNA was determined by excision and
scintillation counting of the retarded and unbound bands, respec-
tively. Ratios of bound to total (total 5 unbound plus bound
activity) were calculated. Kd and Bmax of normal glucose and high
glucose conditioned cells were calculated as: y 5 Bmax * x/(Kd 1
x), with y 5 bound DNA and x 5 total DNA [37] using non-linear
regression (Systat for Windows, Evanston, IL, USA). Best-of-fit
measurement of the regression was calculated from the coefficient
of determination, r2. The mean 6 SE of each condition was
compared by z-test to determine statistical significance (P , 0.05).
Western blots
Twenty-five micrograms of nuclear protein was separated by
either 7% or 10% SDS-PAGE and transferred to nitrocellulose
via a semi-dry technique. Thereafter, the blots were quenched in
PBS 0.1% Tween (PBST), 2% BSA for 120 minutes and incubated
with rabbit polyclonal anti-pan-Fos, anti-cJun, anti-Jun B or
anti-Jun D specific antibodies (Santa Cruz Biotechnology). After
washing in PBST, the blots were incubated with biotinylated
goat-anti-rabbit antibody and streptavidin-horseradish peroxidase
(Zymed Laboratories, Inc., South San Francisco, CA, USA).
Following a final wash in PBS, bands of interest were demon-
strated using enhanced chemiluminescence (ECL; Amersham
Life Sciences, Inc., Arlington Heights, IL, USA) and autoradiog-
raphy film (Kodak X-OMAT, Kodak Inc., Rochester, NY, USA).
Densitometry of the Western blot films assessed differences in the
intensity of the specific bands demonstrated.
In some experiments, nuclear proteins were separated by 10%
SDS-PAGE, transferred to nitrocellulose and immunoblotted
with mouse monoclonal antibody specific for Jun D. After incu-
bation in appropriate secondary antibody, bands of interest were
demonstrated by ECL. Specificity of the protein band as Jun D
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was confirmed by incubating the primary antibody with three
times the excess of the peptide against which the antibody was
raised.
In other experiments, the effects of HG on the phosphorylation
of the JNK kinase SEK 1 were assessed to compliment the JNK
assays. HMC were grown in 5 mM d-glucose, 30 mM l-glucose or 30
mM d-glucose for five days. The cells were then lysed with a buffer
containing 2% SDS and protease inhibitors. Equivalent quantities
of the cell lysates were separated by 12% SDS-PAGE, transferred
to nitrocellulose and immunoblotted with a polyclonal rabbit
antibody specific for the threonine phosphorylated form of SEK1
(anti-phospho-SEK1 Ab; New England Biolabs). After incubation
with appropriate secondary antibody, the bands of interest were
determined by ECL as previously outlined.
Jun NH2-terminal kinase assay
Jun NH2-terminal kinase (JNK) activity was assayed after
immunoprecipitation of JNK proteins as follows. Cells were lysed
in buffer containing 20 mM Hepes, pH 7.9, 0.3 M NaCl, 2 mM
EGTA, 20 mM beta-glycerophosphate, 1 mM DTT, 0.1% Triton
X-100, 1 mM Na3VO4, 400 mM PMSF, 10 mg/ml leupeptin, and 18
mg/ml aprotinin. After clarification, dilution of lysates, as de-
scribed by Cano et al [38], was performed. Protein concentrations
were quantitated by the bicinchinoic acid technique using BSA as
standards. Cell quantity was normalized and the lysates mixed
with 1.0 mg of polyclonal anti-JNK antibody (Santa Cruz Biotech-
nology) overnight at 4°C. The immune complexes were precipi-
tated with protein G-sepharose for one hour, washed three times
in kinase buffer (20 mM Hepes, pH 7.9, 2 mM EGTA, 10 mM
MgCl2, 1 mM DTT, 100 mM Na3VO4, and 25 mM beta-glycero-
phosphate), and resuspended in 40 ml of kinase buffer containing
2 mg of the fusion protein GST-c-Jun(1-79) (Santa Cruz Biotech-
nology), 100 mM ATP and 3 to 5 mCi (g-32P)ATP (NEN-Du Pont).
The reaction was allowed to proceed for 20 minutes at room
temperature and was terminated by the addition of SDS-loading
buffer. Phosphorylated GST-c-Jun was resolved by 12% SDS-
PAGE at 4°C, followed by autoradiography.
RESULTS
High glucose environments increase activator protein-1 binding
to TRE probes
We assessed AP-1 binding after culturing HMC in HG for five
days. This represents a time point at which HMC proliferation is
inhibited [12], matrix production increased and c-fos mRNA
levels suppressed by HG [22]. By EMSA, HMC conditioned for
five days in 30 mM d-glucose demonstrated greater AP-1 binding
than normal glucose conditioned cells (Fig. 1A). To determine if
AP-1 binding was increased prior to five days, EMSA were
performed after conditioning HMC in 30 mM d-glucose for
varying durations. At time points up to three days, AP-1 levels
were similar between 5 mM and 30 mM glucose conditions (Fig.
1B). To ensure that AP-1 levels in HG conditioned cells were not
the result of differences in the rate of AP-1 binding, nuclear
proteins were incubated with TRE oligonucleotides at 5 to 30
minutes. No differences in the rate of TRE binding was apparent
between the normal and high glucose conditioned cells (data not
shown).
The maximal binding (Bmax) of activator protein-1 to DNA is
increased by high glucose conditioning
Electrophoretic mobility shift assays were performed in which
the amount of labeled TRE probe added to 10 mg nuclear protein
was serially increased. Kd and Bmax were calculated as described
in the Methods section. Figure 2 represents the curves of three
binding experiments. The maximal binding of AP-1 (Bmax) was
0.136 6 0.014 ng DNA for cells grown in normal glucose and
0.254 6 0.04 ng DNA for cells grown in high glucose conditions,
which by z-test was statistically significant (P 5 0.01). Kd of
normal glucose cells was 1.65 6 0.40 ng DNA compared to 2.87 6
0.98 ng DNA for high glucose conditioned cells (P 5 0.25).
Fig. 1. Activator protein-1 (AP-1) binding to consensus TPA (phorbol
ester)-responsive element (TRE) oligonucleotide probes is increased in
human mesangial cells (HMC) cultured in high glucose media. (A)
Electrophoretic mobility shift assays (EMSA) were performed with nu-
clear proteins from HMC cultured for five days in 5 mM d-glucose or 30
mM d-glucose media. The retarded bands (arrowhead) represent AP-1
bound to the TRE probe. AP-1 binding is increased in 30 mM d-glucose
cells compared to 5 mM d-glucose cells. The open arrow represents
unbound labeled TRE probe that has migrated to the bottom of the gel.
Specificity of the retarded bands as AP-1 was demonstrated by incubation
of the nuclear proteins with 50 3 unlabeled TRE probe (comp) or 50 3
non-specific oligonucleotide probe (ns comp). Representative of five
separate experiments. (B) EMSA of nuclear proteins obtained at days 3
and 5 demonstrating the increased AP-1 binding of 30 mM d-glucose
treated cells occurred after day 3. Nuclear protein was incubated with 503
excess unlabeled TRE probe (comp) to demonstrate specificity. Repre-
sentative of five separate experiments.
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Enhanced binding of activator protein-1 to DNA is not
explained by changes in its composition
To determine if AP-1 binding was increased due to changes in
the composition of the AP-1 complex, “supershift” assays were
performed. In these experiments, antibodies that recognize pro-
teins known to participate in the formation of the AP-1 complex
were incubated with nuclear proteins prior to EMSA. In both
normal and high glucose conditioned cells, anti-Fos antibodies
caused a supershifted AP-1 band (Fig. 3). Likewise, the addition
of anti-Jun D antibody attenuated the AP-1 band in normal and
high glucose cells. A slight attenuation of the bands was evident
when anti-c-Jun antibody was used. In contrast, the addition of
anti-Jun B, anti-ATF/CREB or a non-specific antibody control
(anti-serum response factor antibody) did not appreciably affect
AP-1 binding.
Enhanced activator protein-1 binding to DNA is not explained
by quantitative changes
By Western blot analyses the quantity of Fos (Fig. 4A) and Jun
D proteins (Fig. 4C) was similar in normal and high glucose
conditioned cells, as confirmed by densitometric evaluation of five
separate immunoblot experiments. The c-Jun Western blots (Fig.
4B) identified the presence of several protein bands with molec-
ular masses higher and lower than the expected 39 kDa of c-Jun
[39]. Faint bands of a molecular mass 38.8 kDa were visualized,
however. This small amount of c-Jun protein corresponded with
the minimal involvement of c-Jun in supershift assays. We were
unable to demonstrate Jun B proteins by Western blotting of
HMC nuclear extracts.
To determine if the 38.8 kDa bands present in Jun D and c-Jun
immunoblots using polyclonal primary antibodies were indeed
Jun proteins, we performed Western blots using a monoclonal
anti-Jun D antibody. A band with a molecular mass of 38.9 kDa
was demonstrated using the monoclonal antibody (Fig. 5). Spec-
ificity of the Jun D band was confirmed by incubation of the
monoclonal antibody with a three times an excess of the peptide
against which the antibody was raised. Incubation of the peptide
with the antibody attenuated the 38.9 kDa band intensity while
preserving nonspecific, higher molecular weight bands.
Fig. 2. Equilibrium binding assays demonstrate increased maximal
binding of activator protein -1 (AP-1) in high glucose conditioned human
mesangial cells (HMC). Ten micrograms of nuclear proteins from three
separate harvests were co-incubated with increasing amounts of 32P-
labeled TRE probe. EMSA were performed and retarded bands excised
after drying. The ratio of bound to total DNA were calculated and plotted.
r2 5 0.99 for normal glucose and 0.985 for high glucose. Symbols are:
(solid line) normal glucose; (dashed line) high glucose.
Fig. 3. Supershift assays identify the composition of activator protein
(AP-1) in human mesangial cells (HMC). Supershift assays were per-
formed using 0.5 mg polyclonal antibody against proteins known to
participate in the AP-1 complex. (A) HMC grown for five days in 5 mM
d-glucose. The addition of anti-Fos and anti-Jun D antibody caused a
supershift and attenuated the AP-1 binding, respectively. Anti-c-Jun
antibody minimally reduced AP-1 binding. A control antibody [polyclonal
anti-serum response factor (SRF)] demonstrated the effects of non-
specific antibody on AP-1 binding. (B) Similar results occurred when
nuclear proteins from HMC cultured for five days in 30 mM d-glucose were
studied. Data shown represent four independent experiments.
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Enhanced activator protein-1 binding to DNA occurs with
l-glucose conditioning
To determine if enhanced AP-1 binding is specific to the
d-isomer of glucose, HMC were cultured in media containing 30
mM d-glucose or 30 mM l-glucose, a glucose isomer that is not
transported intracellularly. Previous studies by Wakisaka, Spiro
and Spiro have shown that l-glucose stimulates matrix protein
production by mesangial cells via a pathway that appears inde-
pendent of osmotic stress [40]. AP-1 binding of HMC cultured in
30 mM l-glucose for five days exceeded that of NG grown cells
(Fig. 6) but was less than that of cells grown in 30 mM d-glucose.
By excision of the retarded AP-1 bands and scintillation counting,
we estimated that l-glucose conditioning increased AP-1 binding
above NG cells by approximately 29.3 6 8% and 30 mM d-glucose
conditioning increased binding by 57.2 6 11% above NG (N 5 3,
P , 0.008).
Reversibility of activator protein-1 binding by culturing human
mesangial cells in normal glucose media
To determine the reversibility of HG-mediated AP-1 binding,
HMC were cultured for five days in normal or high concentrations
Fig. 4. The quantity of activator protein-1 (AP-1) proteins is similar in
normal and high glucose conditioned human mesangial cells (HMC).
SDS-PAGE were performed as described in the Methods section, and
immunoblots were performed using polyclonal antibodies that recognize
Fos proteins and the Jun family members, c-Jun and Jun D. (A) Anti-Fos
immunoblot. Bands with molecular mass 61.7 kDa with similar intensity
are present in 5 mM and 30 mM d-glucose samples. These bands were not
present when non-specific rabbit IgG was used as the primary antibody.
Representative of four experiments. (B) Anti-c-Jun immunoblot. Several
bands were demonstrated using a polyclonal anti-c-Jun antibody. Faint
bands were obvious at 38.8 kDa and no difference between normal and
high glucose samples is evident. Representative of five experiments. (C)
Anti-Jun D immunoblot. Polyclonal anti-Jun D antibody demonstrated a
single band with a molecular mass similar to that visualized in c-Jun
immunoblots (38.8 kDa). No differences between conditions are noted.
Representative of four experiments.
Fig. 5. Confirmation of the 38.8 kDa band as the Jun protein. Monoclo-
nal anti-Jun D antibody was used in the immunoblotting of nuclear
proteins separated by 12% SDS-PAGE. A band with an apparent molec-
ular mass of 38.9 kDa is evident (arrowhead). Specificity of the band as
Jun D protein was accomplished by incubating the monoclonal primary
antibody with 3 3 peptide against which the antibody was raised (comp).
Results represent three independent experiments.
Fig. 6. Elevated l-glucose concentrations increase activator protein-1
(AP-1) binding. Human mesangial cells (HMC) were cultured for five days
in 5 mM d-glucose, 30 mM d-glucose or 30 mM l-glucose. Nuclear proteins
were harvested and EMSA performed. 503 excess unlabeled TRE probe
(comp) was used to demonstrate specificity of the band. Results represent
three independent experiments.
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of d-glucose and then switched to NG media (5 mM d-glucose) for
48 hours. As shown in Figure 7, AP-1 binding was increased in
cells conditioned by HG for five days, and the increase persisted
for at least two days after returning the cells to NG media.
Thereafter, we observed in experiments not represented, that
AP-1 binding returned to levels of NG cells at varying rates.
Effects of protein kinase C inhibition on increased activator
protein-1 binding
To investigate whether the effect of high glucose on AP-1
binding is mediated by PKC, PKC inhibitors were added to HMC
that had been cultured for five days in NG and HG media. Figure
8 demonstrates the results of these experiments. Increasing
concentrations of Calphostin C inhibited AP-1 binding in NG cells
and partially attenuated the binding in HG cells. Increasing
concentrations of Bisindolylmaleimide I also decreased AP-1
binding in both NG and HG cells. AP-1 binding, though attenu-
ated by the PKC inhibitors, remained less in the NG cells than HG
cells. In contrast, PD 098059, at concentrations that we have
shown in other studies [35] inhibits ERK phosphorylation in
HMC, had no effect on AP-1 binding (not shown).
JNK is not activated by high glucose concentrations
In these experiments, JNK proteins harvested from HMC
grown for five days in normal or elevated glucose (d-glucose and
l-glucose) did not demonstrate an increased ability to phosphor-
ylate a JNK substrate, the fusion protein GST-Jun (Fig. 9A). JNK
is classically activated by the JNK kinase, SEK1, which is activated
by serine/threonine phosphorylation. The level of SEK1 threonine
phosphorylation was unaffected by chronic HG media (Fig. 9B),
corroborating the functional JNK assays. In these experiments,
interleukin (IL)-1b (1.1 ng/ml for 30 min) served as a positive
control, and as expected promoted JNK activity and SEK 1
threonine phosphorylation.
DISCUSSION
These studies demonstrate that AP-1 binding to consensus
TRE motifs is increased in HMC cultured in elevated glucose
concentrations for several days. This effect of elevated glucose
conditions is slowly reversible upon returning cells to a media that
contains physiologic concentrations of glucose. Furthermore, we
have established that the increase in AP-1 binding caused by high
concentrations of glucose (1) is not due to an increase in the
quantity of Fos or Jun proteins; (2) is not due to a change in the
composition of the AP-1 complex; and (3) is in part PKC
dependent. These observations suggest that high glucose condi-
tions chronically influence the phosphorylation state of preformed
AP-1.
Binding of AP-1 to the TRE motif occurs at the Jun protein [41,
42], and the involvement of different Jun species in the AP-1
complex is an important determinant of TRE transcription. For
example, Jun B proteins bind DNA but lack an amino-terminus
transactivation domain. Consequently, binding of AP-1 rich in Jun
B inhibits transcription [43, 44]. These current studies demon-
strate that in HMC the predominant form of AP-1 is Fos-Jun D
dimers. Jun D containing AP-1 exists in many cells types as a
pre-formed AP-1 that rapidly mediates transcription via PKC
activation [45], independently of new AP-1 protein synthesis. It is
possible following stimulation by other agonists that the Jun
composition of AP-1 may change; however, we were unable to
demonstrate significant differences in AP-1 composition between
normal and high glucose grown cells. AP-1 proteins dimerize via
hydrophobic interactions between “leucine zipper” regions [46]
and leucine-rich transcription factors other than Jun, such as Fos
and ATF/CREB, can dimerize with Jun and bind TREs [17]. By
complexing with Jun, these other phosphoproteins do not bind the
TRE but do alter DNA binding efficiency [28, 39]. Therefore,
AP-1 composed of Fos-Jun D heterodimers bind DNA more
avidly and bend DNA differently than Jun D homodimers [25, 27,
47, 48].
Without changing the quantity of AP-1 proteins or the compo-
sition of the complex, high glucose environments may increase
AP-1 binding through post-translational modifications of the
complex. A likely mediator of post-translational AP-1 changes is
PKC, which can increase AP-1 binding through phosphorylation
changes of either Jun or Fos proteins or through antagonism of
poorly characterized inhibitors of AP-1 [49]. TRE binding is
inhibited in resting cells through phosphorylation of serine and
threonine residues in the COOH-terminus of Jun, upstream of the
basic region of the DNA binding domain [17]. Dephosphorylation
of these residues reduces the steric hindrance to DNA and
promotes DNA binding. COOH-Jun dephosphorylation follows
PKC activation, although PKC does not directly influence
COOH-Jun phosphorylation. Protein kinase C influences other
kinases that constitutively maintain Jun phosphorylation. Of the
kinases that keep COOH-Jun phosphorylated [50], two intriguing
members are glycogen synthase kinase III (GSK III) [51] and
Fig. 7. Increased activator protein-1 (AP-1) binding is not readily revers-
ible by culturing human mesangial cells (HMC) in normal glucose
conditions. To determine the effects of media glucose normalization on
AP-1 binding, HMC were cultured in normal or high glucose media for
seven days or for seven days in high glucose with changing of the media to
normal glucose concentrations at day 5. Representative of three indepen-
dent experiments.
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casein kinase II (CK II) [52]. Glycogen synthase kinase III is
down-regulated by activated PKC and may mediate AP-1 binding
following PKC activation [53]. Casein kinase II activity, while not
directly affected by PKC, is impaired in the muscle of rats made
diabetic by streptozotocin [54]. Protein kinase C activation also
increases AP-1 binding through the promotion of Jun and Fos
dimerization, which is mediated largely through the phosphoryla-
tion of Fos [55]. Therefore, the post-translational modification of
AP-1 by PKC in high glucose concentrations may involve both
components of AP-1.
We showed that treatment of both normal glucose (NG) and
high glucose (HG) cells with specific PKC inhibitors suppresses
AP-1 binding. These findings suggest a basal level of PKC activity
influences AP-1 binding of cells in vitro. That HG-mediated
binding of AP-1 is attenuated by PKC inhibition is also consistent
with other studies demonstrating high glucose increases PKC
activity acutely, that these effects persist for several days [56] and
that the PKC substrate diacylglycerol is chronically increased in
diabetic states [57]. AP-1 binding by HG was incompletely inhib-
ited by the PKC inhibitors, however, suggesting that other medi-
ators of AP-1 binding may exist in high glucose environments. The
ERK pathway may be activated in states of glucose excess [58] and
ERK activation is known to increase AP-1 through the phosphor-
ylation of Fos proteins [50] and by up-regulating c-fos transcrip-
tion [59, 60]. We showed, however, that the ERK pathway is not
involved in the glucose induction of AP-1 since a potent inhibitor
of MEK, a proximal kinase of ERK, had no appreciable effect on
AP-1 binding. Oxidant stress can also increase AP-1 binding and
redox changes have been described in cells grown in high glucose
conditions or exposed to glycated proteins [61, 62]. In addition,
TGF-b1 can increase AP-1 binding [63, 64] and previous studies
showed both in vitro [65] and in vivo [14, 15, 66] that high glucose
concentrations induce TGF-b production. It is therefore conceiv-
able that in addition to PKC, other pathways may promote AP-1
binding in the diabetic state.
An interesting finding in these studies is the promoting effect of
elevated l-glucose levels on AP-1 binding. Although l-glucose is
considered a metabolically inert isomer, Spiro et al noted glomer-
ular cells cultured in the presence of l-glucose demonstrate
increased glucose utilization and synthesis of excessive amounts of
collagen IV and collagen VI [40]. We did not test the chronic
effects of osmotic agents such as elevated concentrations of
mannitol on AP-1 binding. We therefore cannot exclude an
osmotic activation of AP-1 by l-glucose. Other studies have
recently shown that hyperosmolality [67] or perturbations that
alter cell shape such as cell stretch [68] can acutely increase AP-1
binding in non-renal cells. Similarly, a chronic effect of high
concentrations of mannitol (50 mOsm) has been shown in HMC
to increase matrix protein production [12].
We did demonstrate a low basal level of JNK activity in cultured
HMC, which may represent the effects of serum components on
this pathway. It is plausible that the enhanced AP-1 binding and
Fig. 8. Effects of protein kinase C (PKC) inhibition on activator protein-1 (AP-1) binding. EMSA were performed following the addition of protein
kinase inhibitors to HMC cultures. (A) EMSA of Calphostin C treated cells. Human mesangial cells (HMC) grown in normal (5 mM) and high (30 mM)
d-glucose for five days were treated with increasing quantities (nM) of Calphostin C for one hour. Untreated controls (C) are demonstrated.
Representative EMSA of three independent experiments. (B) EMSA of Bisindolylmaleimide I treated cells. HMC were conditioned with increasing
quantities (nM) of the specific PKC inhibitor, Bisindolylmaleimide I for one hour. Representative of three independent experiments.
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this low level of JNK activity are sufficient to increase TRE gene
transcription above baseline, as may occur in glucose-induced
increases of TGF-b1 mRNA, a TRE-dependent gene [69]. In
contrast, it has recently been suggested that Jun D containing
AP-1 is a poor substrate for JNK compared to other Jun proteins
and that a greater degree of JNK activation is required for TRE
transcriptional changes [70]. Perhaps as important, cells incubated
in high glucose concentrations, demonstrating enhanced binding
of AP-1 to DNA, may be particularly responsive to stimuli such as
ischemia, physical stimuli such as stretching [71] or cytokines that
classically activate JNK [72] but only weakly increase AP-1
binding. This is an intriguing hypothesis because diabetic cells in
vivo may be exposed to such stimuli.
The increases in AP-1/DNA binding mediated by HG appear to
contradict our previous studies demonstrating a decrease in c-fos
mRNA levels in HMC cultured under the same conditions and for
similar periods of time. Low c-fos mRNA may be expected to be
paralleled by low Fos protein synthesis and reduced AP-1 binding.
However, as shown here, a reduction in c-fos mRNA levels caused
by high glucose is not associated with a reduction in Fos protein
concentrations. In fact, suppression of c-fos transcription by high
concentrations of glucose may be the result of the increase in
AP-1 binding because a TRE that mediates suppression of c-fos
transcription exists within its gene promoter [73, 74]. This repres-
sive TRE therefore appears to serve as a negative regulator of
c-fos transcription.
In conclusion, we report the enhanced TRE binding by AP-1 in
HMC grown for five days in elevated glucose concentrations.
AP-1 binding appears to be only partly dependent on the PKC
pathway, which we and others have shown is activated in HMC
conditioned by high glucose concentrations. Therefore, other
potential and undefined mediators of AP-1 binding by HG
environments may exist. JNK activity appears to not differ be-
tween normal glucose and high glucose conditioned cells, despite
these differences in AP-1 binding. We propose that these studies
link high glucose environments to abnormal gene regulation
present in diabetic nephropathy.
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APPENDIX
Abbreviations used in this article are: AP-1, activator protein-1; CK II,
casein kinase II; CRE, cyclic-AMP responsive element; ECL, enhanced
chemiluminescence; ECM, extracellular matrix; EMSA, electrophoretic
mobility shift assay; HG, high glucose; JNK, Jun-NH2-terminal kinase;
MAPK, mitogen activated protein kinase; NG, normal glucose; PBST,
phosphate buffered saline Tween; PKC, protein kinase C; TGF-b, trans-
forming growth factor-B; TRE, TPA (phorbol ester)-responsive element.
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